HB237, titled the Paws Off Act of 2025, would amend the Federal Food, Drug, and Cosmetic Act to require a warning on foods containing xylitol. Under the bill, any food product containing xylitol would be considered misbranded unless its label or labeling includes a warning that specifies xylitol’s toxic effects for dogs if ingested.
The bill directs the Secretary of Health and Human Services, acting through the FDA Commissioner, to issue an interim final rule within 6 months of enactment and a final rule within 1 year to implement the labeling requirement. In practical terms, it would create a federal labeling mandate for manufacturers and sellers of xylitol-containing foods and would add a new misbranding standard under federal food law.
Impact
HB237 would amend Section 403 of the Federal Food, Drug, and Cosmetic Act by adding xylitol-specific labeling requirements to the federal misbranding provisions. This would affect food manufacturers, distributors, and retailers that sell products containing xylitol, requiring them to add a dog-safety warning or risk their products being treated as misbranded under federal law. The bill would also require FDA rulemaking to carry out the new requirement, establishing implementation timelines for both interim and final regulations.
Sentiment
The available record shows no committee transcript, amendments, or recorded votes, so there is no documented debate or formal opposition in the materials provided. Based on the bill text and title, the measure appears to be framed as a consumer and animal-safety initiative, with an emphasis on preventing accidental poisoning of dogs. The absence of recorded votes or hearing discussion means the overall sentiment cannot be measured beyond the bill’s protective, straightforward purpose.
Contention
No specific points of contention are documented in the provided materials. Potential areas of debate, if the bill were considered further, could include whether a federal warning mandate is necessary, how the warning should be worded and displayed, compliance costs for manufacturers, and whether existing voluntary labeling practices are sufficient. However, none of these issues are attributed to any member or stakeholder in the supplied record.